TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05204823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: Chocolate milk shakes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: Chocolate milk shakes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: Chocolate milk shakes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: Chocolate milk shakes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control product
Description: Glucose
Study: NCT05695508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab (Tec)
Description: Subcutaneous administration of Teclistamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab (Tec)
Description: Subcutaneous administration of Teclistamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab (Tec)
Description: Subcutaneous administration of Teclistamab
Study: NCT05836051

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavor
Description: E-liquid flavor chemicals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavor
Description: E-liquid flavor chemicals
Study: NCT06734052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPPA
Description: See CAPPA arm description.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: See health education arm description
Study: NCT04551222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probenecid
Description: 1 gr. orally of probenecid twice daily for 180 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical tablets to probenecid
Study: NCT05765006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relma-cel
Description: CD19-targeted Chimeric AntigenReceptor (CAR) T Cells; Relma-cel be administrated at four dose level:25×106 CAR+ T cells、50×106 CAR+ T cells、100×106 CAR+ T cells/150×106 CAR+ T cells
Study: NCT04336670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality exercise program
Description: Sessions with an exercise program focused in upper and low limbs movements in a virtual enviroment, all performed in standing position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual center therapies (Physical therapy, occupational therapy..)
Study: NCT05695508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab (Tec)
Description: Subcutaneous administration of Teclistamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab (Tec)
Description: Subcutaneous administration of Teclistamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab (Tec)
Description: Subcutaneous administration of Teclistamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab (Tec)
Description: Subcutaneous administration of Teclistamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous administration of Daratumumab
Study: NCT05161091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topical application of Orosol®
Description: Orosol® is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Orosol® every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topical application of Orosol®
Description: Orosol® is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Orosol® every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Topical application of Placebo comparator
Description: Placebo comparator is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Placebo comparator every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Topical application of Placebo comparator
Description: Placebo comparator is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Placebo comparator every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
Study: NCT05514990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO, IV, or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO, IV, or IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05335499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 Dose 1
Description: Treatment period: oral administration for 12 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 Dose 2
Description: Treatment period: oral administration for 12 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 Dose 3
Description: Treatment period: oral administration for 12 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 Dose 4
Description: Treatment period: oral administration for 12 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 Dose 5
Description: Treatment period: oral administration for 12 weeks, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Screening period: oral administration for 2 weeks, QD~* Treatment period: oral administration for 12 weeks, QD
Study: NCT05670769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The training module, which will be developed in line with the continuous midwifery care model, will include home care and counseling of pregnant women with gestational diabetes (glucose monitoring and control, diet, exercise, evaluation of fetal health, etc.).
Study: NCT05125094

Intervention type: DEVICE
Intervention: TACE,Ablation
Description: Transcatheter arterial chemoembolization

Intervention type: DEVICE
Intervention: TACE,Ablation
Description: Transcatheter arterial chemoembolization
Study: NCT05617183

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P47
Description: CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P47
Description: CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
Study: NCT05508009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 1200 mg/Kg
Description: Cyclophosphamide 1200 mg/Kg will be administered as part of the conditioning regimen A prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 1200 mg/Kg
Description: Cyclophosphamide 1200 mg/Kg will be administered as part of the conditioning regimen A prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 100 mg/Kg
Description: Cyclophosphamide 100 mg/Kg will be administered as part of the conditioning regimen B prior to HSCT
Study: NCT05695508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous administration of Daratumumab
Study: NCT05508009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 100 mg/Kg
Description: Cyclophosphamide 100 mg/Kg will be administered as part of the conditioning regimen B prior to HSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation 200 cGy will be administered as part of the conditioning regimen prior to HSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation 200 cGy will be administered as part of the conditioning regimen prior to HSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation 200 cGy will be administered as part of the conditioning regimen prior to HSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation 200 cGy will be administered as part of the conditioning regimen prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT
Study: NCT05695508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: administered i.v. or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: administered i.v. or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: administered i.v. or orally
Study: NCT05049980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical treatment with Mifégyne® and MisoOne®
Description: When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endo-uterine aspiration
Description: When patients arrive in hospital on the day of the surgery, participants will be asked to complete a questionnaire at home 1 week after surgery and return it to investigators.
Study: NCT05695508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: administered i.v. or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: administered i.v. or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: administered i.v. or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: administered i.v. or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: administered i.v. or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administration oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administration oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administration oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administration oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administration oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administration oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administration oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administration oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administration oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Subcutaneous administration of Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Subcutaneous administration of Daratumumab
Study: NCT04696965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correct/recheck strategy
Description: One month after recruitment and every 3 months. 1. Check the inhaler step errors of patients by research assistant; 2.Demonstrate the right way by research assistant; 3. give the inhaler check list with marks of the wrong step(s) patients made to patients and 4. confirm the patients do the right way of the previous wrong step(s).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual verbal instruction
Description: One month after recruitment and every 3 months.1. Check the inhaler step errors of patients by research assistant; 2. Verbal instruction with a physical demonstration will be given by educational nurse in usual care.
Study: NCT04883827

Intervention type: OTHER
Intervention: Blood collection
Description: 20-40 mL of blood to extract cell free DNA

Intervention type: OTHER
Intervention: Blood collection
Description: 20-40 mL of blood to extract cell free DNA

Intervention type: OTHER
Intervention: Urine collection
Description: up to 15 mL of urine to extract cell free DNA

Intervention type: OTHER
Intervention: Urine collection
Description: up to 15 mL of urine to extract cell free DNA
Study: NCT05922917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed-field ablation
Description: application of pulsed-field energy for pulmonary vein isolation and linear ablations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed-field ablation
Description: application of pulsed-field energy for pulmonary vein isolation and linear ablations
Study: NCT04546672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg actual body weight through an intravenous line with brisk flow

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg actual body weight to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be coadministered with Neostigmine at a dose of 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered
Study: NCT05102851

Intervention type: DIAGNOSTIC_TEST
Intervention: Troponin, Lipid profile, HBA1C, Fasting blood glucose level, Creatinine, Body Mass Index
Description: Full history: age, sex, smoking, known diabetes, positive family history high serum creatinine, history of prior percutaneous coronary intervention (PCI) or coronary arteries bypass grafting (CABG), or acute coronary syndrome (ACS). hypertension, diet.
Study: NCT06227364

Intervention type: DIAGNOSTIC_TEST
Intervention: MCI patients
Description: patients with mild cognitive impairment submitted to Magnetic Resonance, neuropsychological evaluation, neurological assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: metabolic patients
Description: patients with obesity and metabolic dysfunction submitted to haematological tests, psychological and neuropsychological evaluation and endocrinologu assessment
Study: NCT06070077

Intervention type: PROCEDURE
Intervention: Chest compressions
Description: 2 minutes of chest compressions

Intervention type: PROCEDURE
Intervention: Chest compressions
Description: 2 minutes of chest compressions
Study: NCT05008536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-NK Cells
Description: 1-3×10\^6 /KG, 3-6×10\^6 /KG, 0.6-1.2×10\^7/KG Treatment follows a lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Study: NCT04791839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab will be supplied by Arcus Biosciences.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab will be supplied by Arcus Biosciences.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab will be supplied by Arcus Biosciences.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab will be supplied by Arcus Biosciences.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant will be supplied by Arcus Biosciences.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant will be supplied by Arcus Biosciences.
Study: NCT05957250

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-FAPI-46 PET/CT
Description: one or two \[68Ga\]Ga-FAPI-46 PET/CT scan(s)
Study: NCT04666467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair
Description: Transvenous approach with a transeptal puncture to place the study device
Study: NCT05503784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BITE Deodorant
Description: BITE natural Deodorant